AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RLAY

Catinazzo Thomas sold $27K of RLAY

Catinazzo Thomas (Chief Financial Officer) sold 1,469 shares of Relay Therapeutics, Inc. (RLAY) at $18.62 on 2026-10-28.

Original reporting
SEC EDGAR · Catinazzo Thomas
Published Oct 30, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RLAY
Bearish
medium confidence
Mentioned
$RLAY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLAYBearishLow
01

Why it matters

The transaction is small relative to total shares, likely causing limited price movement.

02

Market read

A modest insider sell that may slightly weigh on the stock but is unlikely to drive significant moves.

03

What to watch

The CFO's holdings remain sizable, and the sale was not pre‑arranged under a 10b5‑1 plan.

Relevance 3/10Novelty 3/10Timing: post‑market filing

Background

Form 4 filings disclose insider transactions; this filing reports a CFO's open‑market sale.

Company-level read

Ticker impact

$RLAYBearishMedium confidence
Context

CFO Thomas Catinazzo sold 1,469 shares for $27,352, reducing his stake to 103,665 shares.

Expected impact

likely slight downward pressure as the market prices the CFO's sell order.

Evidence & confidence

Small insider sale by a senior officer can be interpreted as a lack of confidence, but the amount is modest relative to total holdings.

Market effects

Sector

Minimal impact on biotech sector; no broader industry signal.

Regional

None; the filing is company‑specific.

Global

Low; only relevant to investors in Relay Therapeutics.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • company
    Relay Therapeutics, Inc.

    Biopharma developing protein‑modulating therapies.

  • person
    Catinazzo Thomas

    Chief Financial Officer of Relay Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RLAY insider trading history →

Related articles

$RLAYHigh

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates Phase 3 ReDiscover-2 trial in 2L breast cancer expected to complete enrollment in mid-2027 Updated data from ongoing Phase 1/2 ReInspire trial of zovegalisib in vascular anomalies t

SEC EDGAR 8-K
$RLAYMed

Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay

SEC EDGAR 8-K
$RLAYLowAI 8/10

Relay Therapeutics Shares Jump 18%

Relay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.

rttnews.com